ABSTRACT
two distinct ways. Reuptake inhibitors bind to transporter proteins but are not transported. These drugs elevate extracellular concentrations of transmitter by blocking transporter-mediated uptake of transmitters from the synapse. Substrate-type releasers bind to transporter proteins and are subsequently transported into the cytoplasm of nerve terminals, releasing neurotransmitter via a process originally described as carrier-mediated exchange (Rudnick and Clark, 1993; . However, the mechanism by which a substrate induces release of neurotransmitter is more complex than a simple exchange of substrate for neurotransmitter. More recent studies of the dopamine transporter have shown that the inward transport of a sub-strate such as amphetamine induces an inward current of sodium, which increases the concentration of internal cellular sodium at the transporter, thereby facilitating reverse transport of the dopamine (Goodwin et al., 2009; Pifl et al., 2009) .
There is growing interest in the use of allosteric modulators (Christopoulos and Kenakin, 2002; Schwartz and Holst, 2007) as medications, including allosteric modulators of the biogenic amine transporters (BATs) (Sanchez, 2006) . Our finding that pretreatment of guinea pig membranes with paroxetine increased the dissociation rate of [ 3 H]cocaine from SERT provided early evidence of allosteric interactions at the biogenic amine transporters (Akunne et al., 1992) . Other studies showed, using rat SERT expressed in human embryonic kidney cells, that imipramine allosterically modulated the ability of citalopram to inhibit [ 3 H]5-HT transport (Sur et al., 1998) . Others reported apparent allosteric interactions between 5-HT and [
3 H]paroxetine binding to human platelet SERT (Andersson and Marcusson, 1989) and between ␤-estradiol and SERT (Chang and Chang, 1999) . More recently, we reported novel allosteric modulators of both DAT (SoRI-9804) (Rothman et al., 2002) and SERT (SoRI-6238 and TB-1-099) (Nandi et al., 2004; Nightingale et al., 2005) . Moreover, Chen et al. (2005) reported evidence for allosteric modulation of [ 3 H](S)-citalopram binding. In 1999, drawing from a library of compounds (maintained by Southern Research Institute, Birmingham, AL) that possessed a diphenylmethyl (benzhydryl) group, we screened, using rat brain tissue assays, compounds for activity in binding assays for DAT, SERT, and NET (unpublished data). This effort identified several possible allosteric modulators of the BATs, and we subsequently examined in greater detail the interaction of selected agents with the BATs. SoRI-6238 and a subsequent compound that was not part of the SoRI library (TB-1-099) were shown to allosterically modulate SERT (Nandi et al., 2004; Nightingale et al., 2005) . Three other compounds were identified as possible allosteric modulators of DAT. SoRI-9804 ( Fig. 1) (Rothman et al., 2002) . More recently (Pariser et al., 2008) , we reported that SoRI-20040 and SoRI-20041 had several properties consistent with an allosteric modulator of DAT. A third compound, SoRI-2827, was studied, but the evidence for it being an allosteric modulator of DAT was less compelling. 
Materials and Methods
Animals. Male Sprague-Dawley rats (Charles River Laboratories, Inc., Wilmington, MA), weighing 300 to 400 g, were used as subjects in these experiments. Rats were housed in standard conditions (lights on from 7:00 AM to 7:00 PM) with food and water freely available. Animals were maintained in facilities fully accredited by the American Association of the Accreditation of Laboratory Animal Care, and experiments were performed in accordance with the Insti- (Rothman et al., 2001; Pariser et al., 2008) .
In Vitro Release Methods. Transporter-mediated release assays were carried out as described previously, with minor modifications (Rothman et al., 2003) . Rats were sacrificed by CO 2 asphyxiation. Tissue from caudate (for DAT assay), or from whole brain minus cerebellum and caudate (for SERT and NET assay), was homogenized in ice-cold 10% sucrose containing 1 M reserpine. For DATmediated release assays, either (Nightingale et al., 2005 ). For the [ 3 H]MPP ϩ efflux experiments, the data of three independent experiments were pooled and fit to one-and two-component dissociation models using MLAB-PC as described previously (Rothman et al., 1991) . Graphs were generated with KaleidaGraph 3.6 software. For most experiments, statistical significance was determined with ANOVA with a post hoc Bonferroni test (Prism version 4.0; GraphPad Software Inc., San Diego, CA). For certain kinetic experiments, two sets of data (data set ␣ and data set ␤) were simultaneously fit (using MLAB-PC) to the two-component dissociation model using the following equations:
Four different constraint conditions were used: 1) unconstrained, 2) four parameters of set ␣ ϭ four parameters of set ␤ (A1 ϭ A3, A2 ϭ A4, K1 ϭ K3, K2 ϭ K4), 3) two kinetic constants of set ␣ ϭ two kinetic constants of set ␤ (K1 ϭ K3, K2 ϭ K4), and 4) two "A" values of set ␣ ϭ two A values of set ␤ (A1 ϭ A3, A2 ϭ A4). An F-test was calculated based on the sum-of-squares for each of the constraint conditions. The threshold for significance was set at P Ͻ 0.01 (Nandi et al., 2004) .
Results
Figure 1 reports the structures of SoRI-9804, SoRI-20040, SoRI-20041, and SoRI-2827. In an initial experiment, we determined the effect of SoRI-20040, SoRI-20041, SoRI-2827 , and SoRI-9804 on control and DAT-mediated DA ([ 3 H]MPP ϩ ) release. In the absence of D-amphetamine (control), only SoRI-9804 had no effect on DA release over the entire concentration range examined ( E max ϭ 7.6 Ϯ 1.6%) had a much smaller, barely detectable effect. Likewise, although SoRI-2827 had a somewhat larger effect than SoRI-20041 (EC 50 ϭ 0.49 Ϯ 0.22 M; E max ϭ 18.6 Ϯ 3.1%), the limited concentration range that did not alter control DA release made further study of this compound difficult. Based on these observations, we focused subsequent experiments on SoRI-9804, SoRI-20040, and SoRI-20041. In our previous study (Pariser et al., 2008) 
82 Ϯ 9* ͓0.21 M͔ 102 Ϯ 2 Experiment 2 (Fig. 4, ͓ 3 H͔DA) (Fig. 7B) . SoRI-2827 enhanced D-amphetamine-induced 5-HT release but that was because of the substantial effect this compound had by itself. Interestingly, SoRI-20041 and SoRI-9804 significantly attenuated D-amphetamine-induced NE release (Fig.  7C) . The degree of attenuation was substantially less than observed for D-amphetamine-induced DA release. With some exceptions, a similar profile of results was observed when different substrates (dopamine and MDA) were used to induce neurotransmitter release. The ineffectiveness of these compounds in the SERT release assay demonstrates that the modulatory effects of SoRI-9804 and SoRI-20040 are selective for DAT. The weaker effect of these same compounds in the NE release assay suggests that similar phenomena might be observed at NET. However, the signal-to-noise ratio of this assay (2:1), as currently implemented, precludes more detailed study.
The (Fig. 2 ). For these experiments, synaptosomes were preloaded with [ 3 H]MPP ϩ for 60 min. Test drugs were then added, and samples were filtered at various times up to 60 min later. As reported in Fig. 8 and Table 3 , D-amphetamine-induced [ 3 H]MPP ϩ efflux was well described by a two-component dissociation model, composed of a fast (A2 and K2) and slow component (A1 and K1), where A1 and A2 are the proportion of efflux attributed to each component, and K1 and K2 are the corresponding rate constants. With 100 nM D-amphetamine, the fast component (A2) contributed 88% to the efflux and had a rate constant of 0.19 Ϯ 0.02 min Ϫ1 . The slow component (A1) contributed 22% to the efflux and had a rate constant of 0.027 Ϯ 0.01 min Ϫ1 . Statistical analysis of the kinetic data showed that D-amphetamine significantly increased the value of A2 and decrease the value of A1 in a dose-dependent manner, yielding an estimated EC 50 value of 13 nM (Fig. 8, inset) , a value somewhat higher than the EC 50 value for D-amphetamineinduced DAT-mediated DA ([ 3 H]MPP ϩ ) release (ϳ6 nM). There were no significant changes in the value of rate constants K1 and K2.
The next experiments compared the effects of various con- The efflux experiments (Fig. 9 , A and B) were fit to oneand two-component dissociation models using MLAB-PC. As reported in Table 4 , the main effect of the lowest dose of cocaine (0.175 M) was to increase A1 from 22% in the presence of 100 nM D-amphetamine alone, to 36%. Although the individual parameter values in the presence of cocaine did not differ significantly from the values in the absence of cocaine, the two overall curves were significantly different (F-test, P Ͻ 0.001). At cocaine doses greater than 0.175 M, a one-component model fit the data as well as the twocomponent model, and cocaine significantly decreased the apparent rate of the slow component (K1) in a dose-dependent manner. The EC 50 value for cocaine reducing K1 was 3.4 M (Fig. 10A) . Thus, the main effect of cocaine was to first eliminate D-amphetamine-induced [ 3 H]MPP ϩ efflux, i.e., reduce A2 to 0, and at higher doses to reduce the apparent rate (K1) of the slow [ 3 H]MPP ϩ efflux. In contrast, the D-amphetamine-induced [ 3 H]MPP ϩ efflux curves in the presence of SoRI-9804 were best fit by the two-component model (Table  5) . SoRI-9804 significantly increased A1 (and decreased A2) in a dose-dependent manner without producing significant changes in the rate constants. The EC 50 value for SoRI-9804 increasing A1 was 0.34 M (Fig. 10B) .
We note that the possible activity of these compounds at other central nervous system binding sites is currently underway via a screen of the receptorome (Roth et al., 2004) . The results will be reported in due course. Pariser et al. (2008) An obvious requirement for studying these compounds on substrate-induced release is to use concentrations that do not directly induce "release." In the DAT-mediated DA ( Various concentrations of D-amphetamine were then added, and samples were filtered at various times up to 60 min later. Each value is the mean Ϯ S.D. The data of three independent experiments were pooled and fit to one-and two-component dissociation experiments using MLAB-PC. In all cases, the two-component model fit significantly better than the one-component model (F-test, P Ͻ 0.002). The best-fit estimates of the kinetic parameters are reported in Table 3 . 3 H]DA in a dose-dependent manner. If one were to define SoRI-20040 as "agonist-like," meaning able to produce an allosteric effect on D-amphetamine-induced DAT-mediated DA release, then SoRI-20041 could be described as an "antagonist-like" allosteric modulator. The structural difference between these two compounds is at first glance minor (Fig. 1 ), but such small changes in structure often produce major changes in pharmacological activity. This suggests that structural modification of these molecules may produce more potent agonist and antagonist DAT allosteric modulators.
Discussion
Several control experiments revealed both the generality of the allosteric effects of the SoRI compounds and as well as their specificity. For example, SoRI-20040 (Fig. 3) and SoRI-9804 (Fig. 4) SoRI-9804 and SoRI-20040 is independent of the DAT substrate used to induce release.
The experiments described in Fig. 7 show that the SoRI compounds specifically modulate the DAT, compared with the SERT and NET. It is noteworthy that SoRI-20040, SoRI- , and samples were filtered at various times up to 60 min later. Each value is the mean Ϯ S.D. The data of three independent experiments were pooled and fit to one-and two-component dissociation experiments using MLAB-PC. The best-fit estimates of the kinetic parameters are reported in Table 4 for cocaine and in Table 5 for SoRI-9804. (Fig.  7C) . The weaker effect of these same compounds in the NE release assay suggests that similar phenomena might be observed at NET. The signal-to-noise ratio of this assay (2:1), as currently implemented, precludes more detailed study of this issue. A generally similar profile of results was observed when different substrates (dopamine and MDA) were used to induce neurotransmitter release. Viewed collectively, these data support the hypothesis that the SoRI compounds specifically modulate the DAT. SoRI-2827 by itself had activity in all three release assays, suggesting a common mechanism that requires further investigation to elucidate. A possible mechanism could be drug-induced increase in the intracellular concentration of Na ϩ , such as produced by monensin and hyperforin (Singer et al., 1999 (Table 3) . D-Amphetamine increased A2 (and decreased A1) in a dose-dependent manner without significantly changing the rate constants. The estimated EC 50 value for D-amphetamine increasing A2 (Fig. 8, inset) (Fig. 9A) . At concentrations of 0.7 M cocaine or greater, the efflux curves were described by a one-component model. The simplest explanation of this observation is that, at this concentration range, cocaine was able to completely block D-amphetamine-induced DAT-mediated DA ([ 3 H]MPP ϩ ) release. Cocaine decreased K1 in a dose-dependent manner, with an EC 50 value of 3.4 M (Fig. 10A) . The cocaine sensitivity of K1 supports the idea that the slow component of efflux reflects DAT-mediated reverse transport of [ 3 H]MPP ϩ (for review, see Chen and Reith, 2000) .
Unlike cocaine, SoRI-9804 slowed the overall rate of Damphetamine (100 nM)-induced [ 3 H]MPP ϩ efflux in an asymptotic manner (Fig. 9B) . All efflux curves were best fit by Table 4 . B, effect of SoRI-9804 on the value of A1, as reported in Table 5. the two-component model (Table 5) , and the chief effect of SoRI-9804 was to increase A1 (and decrease A2) in a dosedependent manner (EC 50 ϭ 0.34 M) without producing significant changes in rate constants (Fig. 10B) . It is of interest to note that the potency of SoRI-9804 is 10 times lower than observed for cocaine in the same assay. Recent studies indicate that DAT can exist in a "reluctant" or "willing" state for D-amphetamine-induced DA efflux (Khoshbouei et al., 2004) depending on N-terminal phosphorylation. Viewed in this context, the effect of SoRI-9804 can be visualized as reducing the proportion of DAT that is in a willing state, thereby reducing the over all efficacy of D-amphetamine-induced DA release. This could potentially result from rendering DAT more susceptible to phosphorylation, or alternatively, shifting DAT to a conformation that is less efficient at exchanging D-amphetamine for [ 3 H]MPP ϩ . Several lines of evidence support the hypothesis that transporters can adopt different conformation states (Ferrer and Javitch, 1998; Reith et al., 2001; Gether et al., 2006) . Table 6 summarizes the results reported in our previous article (Pariser et al., 2008) and the current study. SoRI-9804, SoRI-20040, and SoRI-20041 share several properties. In contrast to cocaine, a classic competitive DAT inhibitor, the SoRI compounds partially inhibited DAT binding, decreased the B max , and slowed the dissociation of [
125 I]RTI-55 from the DAT, classic evidence for allosterism. One of the more striking findings of this study is that SoRI-20041 produced the same effects as SoRI-20040 and SoRI-9804 H͔DA uptake (Zhu and Hexum, 1992) and DAT binding (Reith et al., 1992; Pariser et al., 2008 
